| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2005;80:1388-1393
© 2005 The Society of Thoracic Surgeons
a Department of Cardiothoracic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina
b Department of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
c Department of Pharmacy, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Accepted for publication March 28, 2005.
* Address reprint requests to Dr Kincaid, Department of Cardiothoracic Surgery, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157 (Email: tkincaid{at}wfubmc.edu).
Presented at the Fifty-first Annual Meeting of the Southern Thoracic Surgical Association, Cancun, Mexico, Nov 2–4, 2004.
BACKGROUND: Aprotinin use in cardiac surgery has been associated with mild elevations in serum creatinine but generally has not been associated with an increase in the risk of acute renal failure. In the presence of angiotensin-converting enzyme (ACE) inhibitors, however, aprotinin may contribute to significant reductions in glomerular perfusion pressure. The purpose of this study was to test the hypothesis that the combination of ACE inhibitors and aprotinin cause renal failure after cardiac surgery.
METHODS: The study consisted of a retrospective investigation of all adult patients undergoing coronary artery bypass graft, valve, or combined procedures during the years 2000 to 2002 at a single institution. Aprotinin was administered selectively for reoperations, combined procedures, and other operations deemed to be at higher risk for bleeding. Excluded from analysis were patients with preoperative serum creatinine greater than 1.5 mg/dL, a history of renal failure, emergent or salvage procedures, preoperative use of intraaortic balloon pump, and off-pump procedures. Perioperative renal failure was defined as creatinine greater than 2.0 mg/dL within 72 hours of surgery. Preoperative demographic and intraoperative variables were analyzed with univariate and logistic regression analysis with odds ratio (OR) and bootstrap validation.
RESULTS: A total of 1,209 patients were included. The incidence of perioperative renal failure was 3.5%, and mortality in this group was 48%. Controlling for other demographic and intraoperative variables that may affect renal function (age, sex, diabetes mellitus, hypertension, New York Heart Association class, prior cardiac surgery, valve procedures, cardiopulmonary bypass time, aortic cross-clamp time, lowest hematocrit during cardiopulmonary bypass, transfusions) the preoperative use of ACE inhibitors along with intraoperative use of aprotinin was significantly associated with acute renal failure (OR 2.9, 95% confidence interval [CI]: 1.4 to 5.8, p < 0.0001). The effect of either drug alone was not significant. Other identified risk factors included age (OR 1.2 per year, CI: 1.01 to 1.5, p = 0.035), valve procedure (OR 2.7, CI: 1.3 to 5.7, p = 0.016), lowest hematocrit on cardiopulmonary bypass (OR 2.2, CI: 1.6 to 3.2, p < 0.0001), and transfusions of red blood cells (OR 1.04 per unit, CI: 1.02 to 1.06, p < 0.0001) and platelets (OR 1.7 per unit, CI: 1.2 to 2.4, p = 0.001).
CONCLUSIONS: The combination of preoperative use of ACE inhibitors and intraoperative use of aprotinin should be avoided in cardiac surgery.
This article has been cited by other articles:
|
|
 |
|
  D. L. Ngaage, A. R. Cale, M. E. Cowen, S. Griffin, and L. Guvendik Aprotinin in Primary Cardiac Surgery: Operative Outcome of Propensity Score-Matched Study Ann. Thorac. Surg., October 1, 2008; 86(4): 1195 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.T. Augoustides Aprotinin and renal dysfunction: the role of exposure to angiotensin-converting enzyme inhibitors. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 1104 - 1104. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Arora, S. Rajagopalam, R. Ranjan, H. Kolli, M. Singh, R. Venuto, and J. Lohr Preoperative Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Is Associated with Increased Risk for Acute Kidney Injury after Cardiovascular Surgery Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lindvall, U. Sartipy, T. Ivert, and J. van der Linden Aprotinin is Not Associated With Postoperative Renal Impairment After Primary Coronary Surgery Ann. Thorac. Surg., July 1, 2008; 86(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.T. Augoustides Letter by Augoustides Regarding Article "Aprotinin Does Not Increase the Risk of Renal Failure in Cardiac Surgery Patients" Circulation, June 3, 2008; 117(22): e474 - e474. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Rosner, D. Portilla, and M. D. Okusa Analytic Reviews: Cardiac Surgery as a Cause of Acute Kidney Injury: Pathogenesis and Potential Therapies J Intensive Care Med, January 1, 2008; 23(1): 3 - 18. [Abstract] [PDF]
|
|
|
|
|
|
C. L. Backer, A. M. Kelle, R. D. Stewart, S. C. Suresh, F. N. Ali, R. A. Cohn, R. Seshadri, and C. Mavroudis Aprotinin is safe in pediatric patients undergoing cardiac surgery. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1421 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.T. Augoustides Letter by Augoustides Regarding Article, "Risk Index for Perioperative Renal Dysfunction/Failure: Critical Dependence on Pulse Pressure Hypertension" Circulation, July 31, 2007; 116(5): e119 - e119. [Full Text] [PDF]
|
|
|
|
|
|
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Hogue and M. J. London Aprotinin Use During Cardiac Surgery: A New or Continuing Controversy? Anesth. Analg., November 1, 2006; 103(5): 1067 - 1070. [Full Text] [PDF]
|
|
|
|
|
|
D. Royston Does the combination of aprotinin and Angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann. Thorac. Surg., October 1, 2006; 82(4): 1575 - 1575. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Kincaid, N. D. Kon, and J. W. Hammon Reply. Ann. Thorac. Surg., October 1, 2006; 82(4): 1575 - 1576. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Nielsen Postoperative Renal Failure After Aprotinin Infusion and Spine Operations Anesth. Analg., October 1, 2006; 103(4): 1062 - 1063. [Full Text] [PDF]
|
|
|
|
|
|
L. Groban and J. Butterworth Perioperative management of chronic heart failure. Anesth. Analg., September 1, 2006; 103(3): 557 - 575. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
